Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

iRhythm Holdings (IRTC) Research & Development (2016 - 2025)

iRhythm Holdings (IRTC) has disclosed Research & Development for 11 consecutive years, with $21.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 10.3% to $21.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.6 million through Dec 2025, up 18.4% year-over-year, with the annual reading at $84.6 million for FY2025, 18.4% up from the prior year.
  • Research & Development for Q4 2025 was $21.0 million at iRhythm Holdings, roughly flat from $21.0 million in the prior quarter.
  • The five-year high for Research & Development was $21.5 million in Q1 2025, with the low at $8.5 million in Q1 2021.
  • Average Research & Development over 5 years is $15.1 million, with a median of $15.1 million recorded in 2023.
  • The sharpest move saw Research & Development decreased 23.41% in 2021, then surged 43.96% in 2024.
  • Over 5 years, Research & Development stood at $11.9 million in 2021, then increased by 6.78% to $12.7 million in 2022, then increased by 21.63% to $15.4 million in 2023, then increased by 23.77% to $19.1 million in 2024, then grew by 10.3% to $21.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $21.0 million, $21.0 million, and $21.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.